| CODEXIS INC. DL-,01 |
| USA |
| Gesundheit |
| US1920051067 / A0Q2S4 |
| 4QK (Frankfurt) / CDXS (NASDAQ) |
| FRA:4QK, ETR:4QK, 4QK:GR, NASDAQ:CDXS |
| - |
| http://www.codexis.com/ |
|
Codexis Inc. is a leading enzyme engineering company that develops scalable, sustainable enzymatic solutions for therapeutic manufacturing and development. It leverages the proprietary CodeEvolver protein engineering technology platform to design and..
>Volltext.. |
| 164.57 Mio. EUR |
| 170.94 Mio. EUR |
| 68.64 Mio. EUR |
| -15.26 Mio. EUR |
| -28.12 Mio. EUR |
| -0.32 EUR |
| 64.07 Mio. EUR |
| 32.52 Mio. EUR |
| -16.46 Mio. EUR |
| 4.42 |
| 46.79% |
| 59.77% |
| - |
| - |
| - |
| - |
| CODEXIS |
| 24.07.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|